Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Trial Profile

Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Ramosetron (Primary) ; Aprepitant; Dexamethasone; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms RAPA
  • Most Recent Events

    • 30 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 30 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 03 Sep 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top